Patients with the severe course of COVID-19 infection confirmed by PCR laboratory test will be involved in the study on a voluntary basis.~In accordance with regulatory enactments, these patients receive specialized medical care in specialized medical institutions, where the conduct of the study is planned.~The study is planned as a double-blind, which will be achieved by using Molixan and placebo (0.9% NaCl solution) in the same packaging with the same labeling, indistinguishable in color and smell.~Patients will be randomized in an unpredictable manner using the IWRS system.~It is planned to divide patients into 2 parallel groups:~Group 1. Standard therapy + Molixan;~Group 2. Standard therapy + placebo. The regimen (1 or 2) assigned to each study subject will not be known to either the Investigator or the patient.
Multicenter, prospective, double-blind, placebo-controlled, randomized, parallel-group phase III study.~The study is designed for 2 treatment groups:~Group 1 of the investigational drug - Patients receive standard therapy and the investigational drug.~Group 2 of comparison - Patients receive standard therapy and placebo.